HHS to allow sale of unapproved peptides under review
HHS to allow sale of unapproved peptides under review
The Department of Health and Human Services (HHS) will allow compounding pharmacies to manufacture and sell peptides that have not yet been added to the list of approved substances, advancing access to the those championed by the Make America Healthy Again (MAHA) agenda.
HHS stated in a notice that it would be practicing enforcement discretion — upholding only certain regulations or disciplinary actions — when it comes to manufacturing and selling of the peptides BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax.
This decision essentially gives compounding pharmacies the go-ahead to sell those six peptides without having to worry about regulatory pushback from federal agencies. State-level rules on what and how much compounding pharmacies can make differ and potentially clash with federal rules.
These are........
